Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 25;8(7):e131.
doi: 10.1002/hem3.131. eCollection 2024 Jul.

Parkinson-like neurotoxicity in female patients treated with idecabtagene-vicleucel

Audrey Couturier  1 , Martine Escoffre  1 , Frédérique Leh  2 , Anne-Sophie Villoteau  3 , Xavier Palard  4 , Florence Le Jeune  4 , Olivier Decaux  1 , Thierry Lamy  1 , Roch Houot  1
Affiliations

Parkinson-like neurotoxicity in female patients treated with idecabtagene-vicleucel

Audrey Couturier et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Roch Houot received honoraria from Kite/Gilead, Novartis, Incyte, Janssen, MSD, Takeda, and Roche; and consultancy at Kite/Gilead, 63 Novartis, Bristol‐Myers Squibb/Celgene, ADC Therapeutics, Incyte, Miltenyi. Olivier Decaux received honoraria from Janssen, Celgene/BMS, Amgen, Takeda, GSK, Sanofi, Abbvie, Roche, The Binding Site, Sebia, Menarini‐Stemline, and Pfizer. The remaining authors declare no competing financial interests.

Figures

Figure 1
Figure 1
Clinical, biological, and radiological findings related to neurological toxicity, patient 1. (A) Circulating CAR T‐cells over time, measured by flow cytometry, and correlation to motor and cognitive symptoms. IV Fludarabine allowed a steep decrease in circulating CAR T‐cells. (B) 123I‐FP‐CIT SPECT/CT images showing no presynaptic dopaminergic denervation. (C) [18F]FDG PET/CT images with decreased [18F]FDG activity in both striata (arrows). (D) Repeated axial brain resonance imaging (MRI) with fluid‐attenuated inversion recovery (FLAIR) showing asymmetric bipallidal signal abnormalities (arrows), decreasing over time.
See this image and copyright information in PMC

References

    1. Van Oekelen O, Aleman A, Upadhyaya B, et al. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA‐targeting CAR‐T cell therapy. Nat Med. 2021;27(12):2099‐2103. 10.1038/s41591-021-01564-7 - DOI - PMC - PubMed
    1. Cohen AD, Parekh S, Santomasso BD, et al. Incidence and management of CAR‐T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 2022;12(2):32. 10.1038/s41408-022-00629-1 - DOI - PMC - PubMed
    1. Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene Autoleucel, an anti–B‐cell maturation antigen chimeric antigen receptor T‐cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE‐1 2‐year follow‐up. J Clin Oncol. 2023;41:1265‐1274. 10.1200/JCO.22.00842 - DOI - PMC - PubMed
    1. Karschnia P, Miller KC, Yee AJ, et al. Neurologic toxicities following adoptive immunotherapy with BCMA‐directed CAR T‐cells. Blood. 2023;142:1243‐1248. 10.1182/blood.2023020571 - DOI - PubMed
    1. San‐Miguel J, Dhakal B, Yong K, et al. Cilta‐cel or standard care in lenalidomide‐refractory multiple myeloma. N Engl J Med. 2023;389(4):335‐347. 10.1056/NEJMoa2303379 - DOI - PubMed

LinkOut - more resources